Merck Invests in State-Of-The-Art Biotech Development Facility in Switzerland
Merck KGaA matches lofty R&D goals with €250M investment into a new clinical manufacturing site in Switzerland
As Merck KGaA strives to prove itself as a capable biopharma R&D player, it has begun construction on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
